Oncogenic mutations in gene encoding FLT3 kinase are often detected in acute myeloid
leukaemia (AML) patients, and several potent kinase inhibitors have been developed …

Clinical FLT3 mutations caused poor therapeutic benefits toward the present FLT3 inhibitors,
and degradation of the FLT3 mutant protein may be a promising alternative approach to …

Fms-like tyrosine kinase 3 (FLT3) has been validated as a therapeutic target for acute
myeloid leukemia (AML). While a number of FLT3 kinase inhibitors have been approved for …

Internal tandem duplication (ITD) in the gene encoding FMS-like tyrosine kinase 3
(FLT3)(FLT3-ITD) is the most frequently observed mutation in acute myeloid leukemia …

Acute myeloid leukemia (AML) refers to one of the most lethal blood malignancies
worldwide. FLT3-ITD mutation is recognized as the most common one that predicted a …

Acute myeloid leukemia (AML) patients carrying Fms-like tyrosine kinase 3-internal tandem
duplication (FLT3-ITD) mutations often face a poor prognosis. While some FLT3 inhibitors …

Activating mutations of the class III receptor tyrosine kinase FLT3 are the most frequent
molecular aberration in acute myeloid leukemia (AML). Mutant FLT3 accelerates …

Aim: Approximately 30% of acute myeloid leukemia (AML) patients carry FLT3 tyrosine
kinase domain (TKD) mutations or internal tandem duplication (FLT3-ITD). Currently there is …

FLT3 mutations are the most frequently identified genetic alterations in acute myeloid
leukemia (AML) and are associated with poor prognosis. Multiple FLT3 inhibitors are in …

Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the
subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule …